Main clinical and biological characteristics and outcomes of 587 CLL patients according to TLR/MYD88 mutations
| Characteristic or outcome . | Unmutated (n=564) . | Mutated (n=23) . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Male gender | 338 | 60 | 15 | 65 | NS |
| Age, years | <.0001 | ||||
| Median | 61 | 47 | |||
| Range | 24-94 | 32-72 | |||
| Familiar lymphoid malignancy | 19/564 | 3 | 2/23 | 9 | NS |
| Binet stage | .045 | ||||
| A | 461 | 82 | 17 | 74 | |
| B | 83 | 15 | 3 | 13 | |
| C | 18 | 3 | 3 | 13 | |
| Rai stage | .024 | ||||
| 0 | 315 | 56 | 7 | 30 | |
| I-II | 221 | 39 | 13 | 56 | |
| III-IV | 26 | 5 | 3 | 13 | |
| Lymphocytes, × 109/L | NS | ||||
| Median | 12.6 | 14.2 | |||
| Range | 1.1-130 | 3.3-104 | |||
| Hemoglobin, g/L | NS | ||||
| Median | 139 | 143 | |||
| Range | 45-177 | 91-167 | |||
| Platelets, × 109/L | NS | ||||
| Median | 194 | 183 | |||
| Range | 19-791 | 21-332 | |||
| β2-microglobulin, UNV | 193/476 | 41 | 1/19 | 5 | .001 |
| LDH, UNV | 54/532 | 10 | 1/21 | 5 | NS |
| Monoclonal component | 55/564 | 10 | 4/23 | 17 | NS |
| LDT <1 year | 76/402 | 10 | 1/16 | 6 | NS |
| Mutated IGHV | 255/469 | 54 | 19/21 | 90 | .001 |
| <30% CD38 | 332/501 | 66 | 21/22 | 95 | .002 |
| <20% ZAP-70 | 305/472 | 65 | 21/22 | 95 | .002 |
| Genetics | |||||
| del(13q)(q14.3) | 190/435 | 44 | 12/18 | 67 | .09 |
| Trisomy 12 | 65/438 | 15 | 2/17 | 12 | NS |
| del(11q)(q22.3) | 52/431 | 12 | 2/18 | 6 | NS |
| del(17p)(p13.1) | 17/435 | 4 | 1/18 | 6 | NS |
| Mutated NOTCH1 | 53/498 | 11 | 0/19 | 0 | NS |
| Mutated SF3B1 | 35/352 | 10 | 1/15 | 7 | NS |
| Mutated TP53 | 16/336 | 5 | 0/17 | 0 | NS |
| Treated | 301/564 | 53 | 10/23 | 43 | NS |
| 10-y TTT for Binet A and B patients (%) | 62 | 30 | NS | ||
| 95% CI | 57-67 | 8-52 | |||
| 10-y rate of DLBCL for all patients (%) | 7 | 0 | NS | ||
| 95% CI | 3-10 | ||||
| 10-y OS for all patients (%) | 62 | 100 | .002 | ||
| 95% CI | 55-65 | ||||
| Characteristic or outcome . | Unmutated (n=564) . | Mutated (n=23) . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Male gender | 338 | 60 | 15 | 65 | NS |
| Age, years | <.0001 | ||||
| Median | 61 | 47 | |||
| Range | 24-94 | 32-72 | |||
| Familiar lymphoid malignancy | 19/564 | 3 | 2/23 | 9 | NS |
| Binet stage | .045 | ||||
| A | 461 | 82 | 17 | 74 | |
| B | 83 | 15 | 3 | 13 | |
| C | 18 | 3 | 3 | 13 | |
| Rai stage | .024 | ||||
| 0 | 315 | 56 | 7 | 30 | |
| I-II | 221 | 39 | 13 | 56 | |
| III-IV | 26 | 5 | 3 | 13 | |
| Lymphocytes, × 109/L | NS | ||||
| Median | 12.6 | 14.2 | |||
| Range | 1.1-130 | 3.3-104 | |||
| Hemoglobin, g/L | NS | ||||
| Median | 139 | 143 | |||
| Range | 45-177 | 91-167 | |||
| Platelets, × 109/L | NS | ||||
| Median | 194 | 183 | |||
| Range | 19-791 | 21-332 | |||
| β2-microglobulin, UNV | 193/476 | 41 | 1/19 | 5 | .001 |
| LDH, UNV | 54/532 | 10 | 1/21 | 5 | NS |
| Monoclonal component | 55/564 | 10 | 4/23 | 17 | NS |
| LDT <1 year | 76/402 | 10 | 1/16 | 6 | NS |
| Mutated IGHV | 255/469 | 54 | 19/21 | 90 | .001 |
| <30% CD38 | 332/501 | 66 | 21/22 | 95 | .002 |
| <20% ZAP-70 | 305/472 | 65 | 21/22 | 95 | .002 |
| Genetics | |||||
| del(13q)(q14.3) | 190/435 | 44 | 12/18 | 67 | .09 |
| Trisomy 12 | 65/438 | 15 | 2/17 | 12 | NS |
| del(11q)(q22.3) | 52/431 | 12 | 2/18 | 6 | NS |
| del(17p)(p13.1) | 17/435 | 4 | 1/18 | 6 | NS |
| Mutated NOTCH1 | 53/498 | 11 | 0/19 | 0 | NS |
| Mutated SF3B1 | 35/352 | 10 | 1/15 | 7 | NS |
| Mutated TP53 | 16/336 | 5 | 0/17 | 0 | NS |
| Treated | 301/564 | 53 | 10/23 | 43 | NS |
| 10-y TTT for Binet A and B patients (%) | 62 | 30 | NS | ||
| 95% CI | 57-67 | 8-52 | |||
| 10-y rate of DLBCL for all patients (%) | 7 | 0 | NS | ||
| 95% CI | 3-10 | ||||
| 10-y OS for all patients (%) | 62 | 100 | .002 | ||
| 95% CI | 55-65 | ||||
CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; LDT, lymphocyte doubling time; NS, not significant; UNV, upper normal value.
In numeric values separated by /, right values indicate number of patients with the characteristic and left values indicate total number of cases analyzed.